Product Description: CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity[1].
Applications: Cancer-Kinase/protease
Formula: C28H30N6O3
Citations: bioRxiv. 2021 Feb 5./bioRxiv. 2020 Apr. /Cancer Discov. 2019 Feb;9(2):230-247./Commun Biol. 2021 May 24;4(1):617./Oncol Rep. 2024 Aug;52(2):101./Front Oncol. 2024 Aug 9:14:1447807.
References: [1]Liu Y, et al. Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent. ACS Med Chem Lett. 2016 May 6;7(7):671-5./[2]Mason JM, et al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
CAS Number: 1610759-22-2
Molecular Weight: 498.58
Compound Purity: 99.77
Research Area: Cancer
Solubility: DMSO : 1.67 mg/mL (ultrasonic)
Target: Mps1
Deutsch
English
